Metabolic abnormalities in an early psychosis service: A retrospective, naturalistic cross-sectional study

Early Intervention in Psychiatry

Volumn 5, Issue 2, 2011, Pages 108-114

  Curtis, Jackie ^a,b   Henry, Catherine ^a   Watkins, Andrew ^a   Newall, Hannah ^c   Samaras, Katherine ^d,e   Ward, Philip B ^b,f  

^a South Eastern Sydney Local Health Network   (Australia)

^b Schizophrenia Research Institute   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d ST VINCENT S HOSPITAL   (Australia)

^e GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^f SCHIZOPHRENIA RESEARCH INSTITUTE   (Australia)

Author keywords

Antipsychotic monitoring; First episode psychosis; Metabolic syndrome

Indexed keywords

AMISULPRIDE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; CLOZAPINE; LITHIUM; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; VALPROIC ACID; ZIPRASIDONE;

ADOLESCENT; ADULT; ARTICLE; BODY MASS; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; METABOLIC SYNDROME X; NATURALISTIC INQUIRY; OBESITY; PRIORITY JOURNAL; PSYCHOSIS; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME; WAIST CIRCUMFERENCE; WEIGHT GAIN;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BODY MASS INDEX; COMMUNITY MENTAL HEALTH SERVICES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; OVERWEIGHT; PREVALENCE; PSYCHOTIC DISORDERS; RETROSPECTIVE STUDIES; WAIST CIRCUMFERENCE; WEIGHT GAIN;

EID: 79955471214     PISSN: 17517885     EISSN: 17517893     Source Type: Journal    
DOI: 10.1111/j.1751-7893.2011.00262.x     Document Type: Article

References (35)

1. Cameron AJ, Dunstan DW, Owen N etal. Health and mortality consequences of abdominal obesity: evidence from the AusDiab study. Med J Aust 2009; 191: 202-8.
2. De Hert M, Schreurs V, Vancampfort D, Van Winkel R. Metabolic syndrome in people with schizophrenia: a review. World Psychiatr 2009; 8: 15-22.
3. Newcomer JW, Hennekens CH. Severe mental illness and risk of cardiovascular disease. JAMA 2007; 298: 1794-6.
4. Scheen AJ, De Hert MA. Abnormal glucose metabolism in patients treated with antipsychotics (Review). Diabetes Metab 2007; 33: 169-75.
5. Lambert TJ, Chapman LH, Consensus Working Group. Diabetes, psychotic disorders and antipsychotic therapy: a consensus statement. Med J Aust 2004; 181: 544-8.
6. Waterreus AJ, Laugharne JD. Screening for the metabolic syndrome in patients receiving antipsychotic treatment: a proposed algorithm. Med J Aust 2009; 190: 185-9.
7. Lambert TJ, Newcomer JW. Are the cardiometabolic complications of schizophrenia still neglected? Barriers to care. Med J Aust 2009; 190(Suppl. 4): S39-42.
8. Haupt DW, Rosenblatt LC, Kim E, Baker RA, Whitehead R, Newcomer JW. Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents. Am J Psychiatry 2009; 166: 345-53.
9. Addington J, Mansley C, Addington D. Weight gain in first-episode psychosis. Can J Psychiatry 2003; 48: 272-6.
10. Addington J, Saeedi H, Addington D. Weight gain in first-episode psychosis over three years. Schizophr Res 2006; 86: 335-6.
11. Alvarez-Jimenez M, Gonzalez-Blanch C, Crespo-Facorro B etal. Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders - a systematic critical reappraisal. CNS Drugs 2008; 22: 547-62.
12. Perez-Iglesias R, Crespo-Facorro B, Martinez-Garcia O etal. Weight gain induced by haloperidol, risperidone and olanzapine after 1year: findings of a randomized clinical trial in a drug-naive population. Schizophr Res 2008; 99: 13-22.
13. Saddichha S, Ameen S, Akhtar S. Predictors of antipsychotic-induced weight gain in first-episode psychosis - conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol. J Clin Psychopharmacol 2008; 28: 27-31.
14. Strassnig M, Miewald J, Keshavan M, Ganguli R. Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis. Schizophr Res 2007; 93: 90-8.
15. Zipursky RB, Gu HB, Green AI etal. Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry 2005; 187: 537-43.
16. De Hert M, Schreurs V, Sweers K etal. Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review. Schizophr Res 2008; 101: 295-303.
17. Patel JK, Buckley PF, Woolson S etal. Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study. Schizophr Res 2009; 111: 9-16.
18. Perez-Iglesias R, Mata I, Pelayo-Teran JM etal. Glucose and lipid disturbances after 1year of antipsychotic treatment in a drug-naive population. Schizophr Res 2009; 107: 115-21.
19. Saddichha S, Ameen S, Akhtar S. Metabolic syndrome in drug-naive first-episode psychosis treated with atypical antipsychotics. Aust N Z J Psychiatry 2007; 41: 629.
20. Sengupta S, Parrilla-Escobar MA, Klink R etal. Are metabolic indices different between drug-naive first-episode psychosis patients and healthy controls? Schizophr Res 2008; 102: 329-36.
21. Verma S, Liew A, Subramaniam M, Poon LY. Effect of treatment on weight gain and metabolic abnormalities in patients with first-episode psychosis. Aust N Z J Psychiatry 2009; 43: 812-17.
22. Perez-Iglesias R, Crespo-Facorro B, Amado JA etal. A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone. J Clin Psychiatry 2007; 68: 1733-40.
23. Fernandez-Egea E, Bernardo M, Donner T etal. Metabolic profile of antipsychotic-naive individuals with non-affective psychosis. Br J Psychiatry 2009; 194: 434-8.
24. Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia (see comment). Am J Psychiatry 2003; 160: 284-9.
25. Saddichha S, Manjunatha N, Ameen S, Akhtar S. Diabetes and schizophrenia - effect of disease or drug? Results from a randomized, double-blind, controlled prospective study in first-episode schizophrenia. Acta Psychiatr Scand 2008; 117: 342-7.
26. Spelman LM, Walsh PI, Sharifi N, Collins P, Thakore JH. Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia. Diabet Med 2007; 24: 481-5.
27. Verma SK, Subramaniam M, Liew A, Poon LY. Metabolic risk factors in drug-naive patients with first-episode psychosis. J Clin Psychiatry 2009; 70: 997-1000.
28. Alberti K, Zimmet P, Shaw J. The metabolic syndrome - a new worldwide definition. Lancet 2005; 366: 1059-62.
29. Hennekens CH. Increasing global burden of cardiovascular disease in general populations and patients with schizophrenia. J Clin Psychiatry 2007; 68: 4-7.
30. John AP, Koloth R, Dragovic M, Lim SCB. Prevalence of metabolic syndrome among Australians with severe mental illness. Med J Aust 2009; 190: 176-9.
31. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents (see comment). JAMA 2009; 302: 1765-73.
32. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004; 363: 157-63.
33. Saddichha S, Manjunatha N, Ameen S, Akhtar S. Metabolic syndrome in first episode schizophrenia - a randomized double-blind controlled, short-term prospective study. Schizophr Res 2008; 101: 266-72.
34. Gross C, Blasey CM, Roe RL, Allen K, Block TS, Belanoff JK. Mifepristone treatment of olanzapine-induced weight gain in healthy men. Adv Ther 2009; 26: 959-69.
35. Crabb J, McAllister M, Blair A. Who should swing the stethoscope? An audit of baseline physical examination and blood monitoring on new patients accepted by an early intervention in psychosis team. Early Interv Psychiatry 2009; 3: 312-16.